Application of purine metabolism marker in preparation of reagent for screening and diagnosing acquired drug resistance of lung cancer molecular targeted drug

Abstract

The invention provides application of a purine metabolism marker in preparation of a reagent for screening and diagnosing acquired drug resistance of a lung cancer molecular targeted drug. The purine metabolism marker is one or more of adenosine monophosphate, guanosine monophosphate, inosine monophosphate, xanthosine monophosphate, adenosine, guanosine, inosine, xanthosine, adenine, guanine, hypoxanthine, xanthine and uric acid. The metabolic marker has good diagnostic potential for acquired drug resistance of the lung cancer molecular targeted drug, can be used for diagnosis and curative effect monitoring of acquired drug resistance of the lung cancer molecular targeted drug, and has good guiding significance for development of subsequent clinical application research.

Description

technical field [0001] The invention relates to the field of biological detection, in particular to the application of purine metabolic markers in the preparation of acquired drug resistance screening and diagnostic reagents for lung cancer molecular targeting drugs. Background technique [0002] Lung cancer is the malignant tumor with the highest mortality rate in my country. For lung cancer with activating mutations of epidermal growth factor (EGFR), molecular targeted drug therapy such as epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) targeting the driver gene has made significant progress. The proportion of lung cancer patients with EGFR activating mutations in the East Asian population is much higher than that of European and American patients. Therefore, EGFR-TKI targeted therapy is of great significance to Chinese lung cancer patients. However, after the initial treatment is effective, the tumor will inevitably acquire drug resistance to EGFR-...

AI Technical Summary

Problems solved by technology

However, after the initial treatment is effective, the tumor will inevitably acquire drug resistance to EGFR-TKI, which greatly limits the ultimate clinical value of this type of drug

[0003] At present, the most widely used clinical drug resistance detection methods mainly focus on the detection of EGFR and KRAS gene mutations. This method has problems such as poor sensitivity and low detection efficiency. Therefore, a large number of studies are looking for new biomarkers for drug resistance detection. thing

Images